These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15117932)

  • 21. [New therapeutic strategies with teicoplanin].
    Carbone E; Nacinovich F; Stamboulian D
    Medicina (B Aires); 2002; 62 Suppl 2():25-9. PubMed ID: 12481485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections.
    Finney MS; Crank CW; Segreti J
    Curr Med Res Opin; 2005 Dec; 21(12):1923-6. PubMed ID: 16368041
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
    Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dalbavancin: a novel lipoglycopeptide antibacterial.
    Pope SD; Roecker AM
    Pharmacotherapy; 2006 Jul; 26(7):908-18. PubMed ID: 16803423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early experience with linezolid for infections in orthopaedics.
    Harwood PJ; Talbot C; Dimoutsos M; Sunderland G; Shaw D; Wilcox MH; Giannoudis PV
    Injury; 2006 Sep; 37(9):818-26. PubMed ID: 16620816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimizing therapy for vancomycin-resistant enterococci (VRE).
    Linden PK
    Semin Respir Crit Care Med; 2007 Dec; 28(6):632-45. PubMed ID: 18095227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G; Rossolini GM
    Clin Microbiol Infect; 2009 Mar; 15(3):218-23. PubMed ID: 19335369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of linezolid in children: an overview of recent advances.
    Velissariou IM
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):947-52. PubMed ID: 17181410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orthopaedic infections: organisms and antibiotic sensitivity.
    Yusof MI; Yusof AH
    Med J Malaysia; 2004 Dec; 59(5):574-7. PubMed ID: 15889557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Experience with linezolid therapy in children with osteoarticular infections.
    Chen CJ; Chiu CH; Lin TY; Lee ZL; Yang WE; Huang YC
    Pediatr Infect Dis J; 2007 Nov; 26(11):985-8. PubMed ID: 17984803
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical experience with daptomycin: bacteraemia and endocarditis.
    Levine DP
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii35-39. PubMed ID: 18829724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series.
    Rao N; Hamilton CW
    Diagn Microbiol Infect Dis; 2007 Oct; 59(2):173-9. PubMed ID: 17574788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibiotics for gram-positive bacterial infections: vancomycin, quinupristin-dalfopristin, linezolid, and daptomycin.
    Lundstrom TS; Sobel JD
    Infect Dis Clin North Am; 2004 Sep; 18(3):651-68, x. PubMed ID: 15308280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current and emerging serious Gram-positive infections.
    Menichetti F
    Clin Microbiol Infect; 2005 May; 11 Suppl 3():22-8. PubMed ID: 15811021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New drugs for Gram-positive uropathogens.
    Wagenlehner FM; Naber KG
    Int J Antimicrob Agents; 2004 Sep; 24 Suppl 1():S39-43. PubMed ID: 15364305
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains.
    Jones RN
    Clin Infect Dis; 2006 Jan; 42 Suppl 1():S13-24. PubMed ID: 16323115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fighting infections due to multidrug-resistant Gram-positive pathogens.
    Cornaglia G
    Clin Microbiol Infect; 2009 Mar; 15(3):209-11. PubMed ID: 19335367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Teicoplanin in the treatment of bone and joint infections due to methicillin resistant staphylococci. Experience in adult patients].
    Pensotti C; Nacinovich F; Vidiella G; Carbone E; Marin M; Di Stéfano C; Stamboulian D
    Medicina (B Aires); 2002; 62 Suppl 2():40-7. PubMed ID: 12481488
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linezolid for the treatment of adults with bone and joint infections.
    Falagas ME; Siempos II; Papagelopoulos PJ; Vardakas KZ
    Int J Antimicrob Agents; 2007 Mar; 29(3):233-9. PubMed ID: 17204407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activities of cefotaxime, vancomycin, quinupristin/dalfopristin, linezolid and other antibiotics alone and in combination against Propionibacterium acnes isolates from central nervous system infections.
    Mory F; Fougnot S; Rabaud C; Schuhmacher H; Lozniewski A
    J Antimicrob Chemother; 2005 Feb; 55(2):265-8. PubMed ID: 15590714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.